119 related articles for article (PubMed ID: 6313655)
1. Activator protein for the degradation of globotriaosylceramide by human alpha-galactosidase.
Gärtner S; Conzelmann E; Sandhoff K
J Biol Chem; 1983 Oct; 258(20):12378-85. PubMed ID: 6313655
[TBL] [Abstract][Full Text] [Related]
2. Activator protein required for the enzymatic hydrolysis of cerebroside sulfate. Deficiency in urine of patients affected with cerebroside sulfatase activator deficiency and identity with activators for the enzymatic hydrolysis of GM1 ganglioside and globotriaosylceramide.
Li SC; Kihara H; Serizawa S; Li YT; Fluharty AL; Mayes JS; Shapiro LJ
J Biol Chem; 1985 Feb; 260(3):1867-71. PubMed ID: 2981875
[TBL] [Abstract][Full Text] [Related]
3. Plasma alpha-galactosidase A:properties and comparisons with tissue alpha-galactosidases.
Bishop DF; Sweeley CC
Biochim Biophys Acta; 1978 Aug; 525(2):399-409. PubMed ID: 210818
[TBL] [Abstract][Full Text] [Related]
4. Identity of the activator proteins for the enzymatic hydrolysis of sulfatide, ganglioside GM1, and globotriaosylceramide.
Vogel A; Fürst W; Abo-Hashish MA; Lee-Vaupel M; Conzelmann E; Sandhoff K
Arch Biochem Biophys; 1987 Dec; 259(2):627-38. PubMed ID: 3426245
[TBL] [Abstract][Full Text] [Related]
5. Acid glycohydrolase in Chinese hamster with spontaneous diabetes. I. Depressed levels of renal alpha-galactosidase and beta-galactosidase.
Chang AY
Biochim Biophys Acta; 1978 Feb; 522(2):491-502. PubMed ID: 23847
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting the hydrolysis of ceramide-3 by alpha-galactosidase A from human liver.
Schram AW; Hamers MN; Samson MR; Cordus S; De Jonge A; Brown I; Robinson D; Tager JM
Biochim Biophys Acta; 1979 May; 568(1):59-70. PubMed ID: 36166
[TBL] [Abstract][Full Text] [Related]
7. A triple-binding-domain model explains the specificity of the interaction of a sphingolipid activator protein (SAP-1) with sulphatide, GM1-ganglioside and globotriaosylceramide.
Wynn CH
Biochem J; 1986 Dec; 240(3):921-4. PubMed ID: 3827882
[TBL] [Abstract][Full Text] [Related]
8. Affinity purification of alpha-galactosidase A from human spleen, placenta, and plasma with elimination of pyrogen contamination. Properties of the purified splenic enzyme compared to other forms.
Bishop DF; Desnick RJ
J Biol Chem; 1981 Feb; 256(3):1307-16. PubMed ID: 6256390
[TBL] [Abstract][Full Text] [Related]
9. Properties of mouse alpha-galactosidase.
Lusis AJ; Paigen K
Biochim Biophys Acta; 1976 Jul; 437(2):487-97. PubMed ID: 8104
[TBL] [Abstract][Full Text] [Related]
10. [Substrate specificity of multiple forms of human alpha-D-galactosidase and alpha-D-fucosidase].
Baskaeva EM; Shono NI; Kozlova IK; Vidershaĭn GIa
Biokhimiia; 1989 Mar; 54(3):421-6. PubMed ID: 2546612
[TBL] [Abstract][Full Text] [Related]
11. Properties of immobilized fig alpha-galactosidase and effect on ceramide-3 content of plasma from patients with Fabry's disease.
Schram AW; Hamers MN; Oldenbroek-Haverkamp E; Strijland A; de Jonge A; van den Bergh FA; Tager JM
Biochim Biophys Acta; 1978 Dec; 527(2):456-64. PubMed ID: 31916
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a glycoprotein alpha-galactosidase from lentil seeds (Lens culinaris).
Dey PM; Del Campillo EM; Lezica RP
J Biol Chem; 1983 Jan; 258(2):923-9. PubMed ID: 6296089
[TBL] [Abstract][Full Text] [Related]
13. I-Cell disease: isoelectric focusing, concanavalin A-Sepharose 4B binding and kinetic properties of human liver acid beta-D-galactosidases.
Miller AL
Biochim Biophys Acta; 1978 Jan; 522(1):174-86. PubMed ID: 413580
[TBL] [Abstract][Full Text] [Related]
14. Studies on human liver alpha-galactosidases. I. Purification of alpha-galactosidase A and its enzymatic properties with glycolipid and oligosaccharide substrates.
Dean KJ; Sweeley CC
J Biol Chem; 1979 Oct; 254(20):9994-10000. PubMed ID: 39940
[No Abstract] [Full Text] [Related]
15. Accumulation of globotriaosylceramide in a case of leiomyosarcoma.
Li SC; Kundu SK; Degasperi R; Li YT
Biochem J; 1986 Dec; 240(3):925-7. PubMed ID: 3827883
[TBL] [Abstract][Full Text] [Related]
16. [Biochemical and pathological studies on a carrier of Fabry's disease manifesting bouts of pain in the extremities].
Katayama M; Kobayashi T; Ohnishi A; Goto I; Kuroiwa Y
Rinsho Shinkeigaku; 1984 Jun; 24(6):575-80. PubMed ID: 6094070
[No Abstract] [Full Text] [Related]
17. A protein activator of galactosylceramide beta-galactosidase.
Wenger DA; Sattler M; Roth S
Biochim Biophys Acta; 1982 Sep; 712(3):639-49. PubMed ID: 7126630
[TBL] [Abstract][Full Text] [Related]
18. The determination of phytosphingosine-containing globotriaosylceramide from human kidney in the presence of lactosylceramide.
Röder B; Dabrowski J; Dabrowski U; Egge H; Peter-Katalinić J; Schwarzmann G; Sandhoff K
Chem Phys Lipids; 1990 Mar; 53(1):85-9. PubMed ID: 2162261
[TBL] [Abstract][Full Text] [Related]
19. Properties of the residual alpha-galactosidase activity in the tissues of a Fabry hemizygote.
Rietra PJ; Van den Bergh FA; Tager JM
Clin Chim Acta; 1975 Aug; 62(3):401-13. PubMed ID: 809216
[TBL] [Abstract][Full Text] [Related]
20. Enzyme therapy XVII: metabolic and immunologic evaluation of alpha- galactosidase A replacement in Fabry disease.
Desnick RJ; Dean KJ; Grabowski GA; Bishop DF; Sweeley CC
Birth Defects Orig Artic Ser; 1980; 16(1):393-413. PubMed ID: 6256019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
